Clinical Trial Management System, OnCore to support Enterprise-wide subject tracking

SCTR Communications
January 25, 2022
What's new

Phase I

Effective March 1, 2022, all NEW clinical research studies at MUSC meeting the criteria below will be entered into and managed in the Clinical Trial Management System (CTMS), OnCore to support Enterprise-wide subject tracking and financial invoicing goals.

  • All Cancer-related studies reviewed by the Protocol Review Committee
  • Any other Human Subjects Research studies that include at least one of the following:
    • Prospective enrollment of subjects (Expedited and Full Board IRB Reviews)
    • Studies utilizing Participant Outreach Recruitment (POR) Service
    • All studies requiring registration and results reporting
    • Industry Sponsored trial invoicing (milestone and invoiceable driven invoicing)

As new studies are submitted in SPARC, the studies will be entered into OnCore to be managed by study teams. The OCR is building the calendar and protocol record into OnCore to support the study teams participant and financial tracking. Protocol specific training will be provided as needed to individual study teams.

For additional information about OnCore as well as training requests please visit our support site on the horseshoe or contact the team - Additional details will be provided in upcoming communications.

Related Links

MUSC Office of Clinical Research

Clinical Trial Management System